Theralase files prospectus to raise up to C$100M for cancer and virus drug development

Theralase Technologies Inc. has filed a final base shelf prospectus allowing it to raise up to C$100 million over 25 months through the sale of various securities. This funding will support the development of its cancer, virus, and bacteria treatment platforms, including a key clinical program for non-muscle invasive bladder cancer. The company emphasizes that it currently has no immediate plans to issue securities but seeks flexible financing to advance its clinical and commercial milestones. This move aims to strengthen Theralase's ability to create long-term shareholder value by supporting ongoing research and development efforts.